ReviewChemical communications (Cambridge, England)2014
Glycans in pathogenic bacteria--potential for targeted covalent therapeutics and imaging agents.
Review in Chemical communications (Cambridge, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Examination of Acetylated Monosaccharides as Metabolic Probes in Bacteria.ACS infectious diseases · 2025Article
- Iron-Catalyzed GlycalTetrahedron letters · 2025Article
- Stereoselective Glycosylation for 1,2-Journal of the American Chemical Society · 2024Article
- Article
- Glycoengineering with neuraminic acid analogs to label lipooligosaccharides and detect native sialyltransferase activity in gram-negative bacteria.Glycobiology · 2024Article
- Soluble Human Lectins at the Host-Microbe Interface.Annual review of biochemistry · 2024Review
- Minimalist TetrazineJournal of the American Chemical Society · 2024Article
- Serum antibody screening using glycan arrays.Chemical Society reviews · 2024Review
- Biomaterials-mediated ligation of immune cell surface receptors for immunoengineering.Immuno-oncology technology · 2024Review
- Article
- Thioglycosides Act as Metabolic Inhibitors of Bacterial Glycan Biosynthesis.ACS infectious diseases · 2023Article
- Preference of Bacterial Rhamnosyltransferases for 6-Deoxysugars Reveals a Strategy To Deplete O-Antigens.Journal of the American Chemical Society · 2023Article
- Feedback Inhibition of Bacterial Nucleotidyltransferases by Rare Nucleotide l-Sugars Restricts Substrate Promiscuity.Journal of the American Chemical Society · 2023Article
- The Attenuation Mechanism and Live Vaccine Potential of a Low-VirulenceJournal of microbiology and biotechnology · 2023Article
- Chemical tools to study bacterial glycans: a tale from discovery of glycoproteins to disruption of their function.Israel journal of chemistry · 2023Article
- Glycan-Based Electrochemical Biosensors: Promising Tools for the Detection of Infectious Diseases and Cancer Biomarkers.Molecules (Basel, Switzerland) · 2022Review
- Recent advances in developing active targeting and multi-functional drug delivery systems via bioorthogonal chemistry.Signal transduction and targeted therapy · 2022Review
- Expanding the Substrate Scope of a Bacterial Nucleotidyltransferase via Allosteric Mutations.ACS infectious diseases · 2022Article
- Selective Exoenzymatic Labeling of Lipooligosaccharides of Neisseria gonorrhoeae with α2,6-Sialoside Analogues.Chembiochem : a European journal of chemical biology · 2022Article
- Outer Membrane Vesicles: An Emerging Vaccine Platform.Vaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A substantial obstacle to the existing treatment of bacterial diseases is the lack of specific probes that can be used to diagnose and treat pathogenic bacteria in a selective manner while leaving the microbiome largely intact. To tackle this problem, there is an urgent need to develop pathogen-specific therapeutics and diagnostics. Here, we describe recent evidence that indicates distinctive glycans found exclusively on pathogenic bacteria could form the basis of targeted therapeutic and diagnostic strategies. In particular, we highlight the use of metabolic oligosaccharide engineering to covalently deliver therapeutics and imaging agents to bacterial glycans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.